Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Paheli Maru, Beena Brahmbhatt, Sangita Vanik, Sneha Kakoty
BACKGROUND: Mediastinal lymphoma is uncommon, and only 10% of lymphomas occur primarily in the mediastinum. Very few Indian studies have discussed the frequency, presentation, and diagnostic approach of primary mediastinal lymphomas. AIMS: This study aims to detail the frequency and histological features of mediastinal lymphomas diagnosed in our Institute, discuss the close differentials, and compare the morphological and immunohistochemistry (IHC) features of primary mediastinal lymphomas...
February 14, 2024: Indian Journal of Pathology & Microbiology
#22
JOURNAL ARTICLE
Fereshteh Yousefirizi, Ivan S Klyuzhin, Joo Hyun O, Sara Harsini, Xin Tie, Isaac Shiri, Muheon Shin, Changhee Lee, Steve Y Cho, Tyler J Bradshaw, Habib Zaidi, François Bénard, Laurie H Sehn, Kerry J Savage, Christian Steidl, Carlos F Uribe, Arman Rahmim
PURPOSE: Total metabolic tumor volume (TMTV) segmentation has significant value enabling quantitative imaging biomarkers for lymphoma management. In this work, we tackle the challenging task of automated tumor delineation in lymphoma from PET/CT scans using a cascaded approach. METHODS: Our study included 1418 2-[18 F]FDG PET/CT scans from four different centers. The dataset was divided into 900 scans for development/validation/testing phases and 518 for multi-center external testing...
February 8, 2024: European Journal of Nuclear Medicine and Molecular Imaging
#23
REVIEW
Prateek Pophali, Juan Carlos Varela, Jacalyn Rosenblatt
Malignant cells are known to evade immune surveillance by engaging immune checkpoints which are negative regulators of the immune system. By restoring the T-lymphocyte mediated anti-tumor effect, immune checkpoint inhibitors (ICI) have revolutionized the treatment of solid tumors but have met rather modest success in hematological malignancies. Currently, the only FDA approved indications for ICI therapy are in classic hodgkin lymphoma and primary mediastinal B cell lymphoma. Multiple clinical trials have assessed ICI therapy alone and in combination with standard of care treatments in other lymphomas, plasma cell neoplasms and myeloid neoplasms but were noted to have limited efficacy...
2024: Frontiers in Oncology
#24
JOURNAL ARTICLE
Ching-Fen Yang, Yu-Ting Yu, Shu-Hsien Wang, Ya-Ping Chen, Tsai-Yun Chen, Chih-Yi Hsu, L Jeffrey Medeiros, Kung-Chao Chang
BLS-type diffuse large B-cell lymphoma (DLBCL) denotes an uncommon, aggressive variant of DLBCL presenting initially in bone marrow, liver and spleen without lymphadenopathy or mass lesion. Patients with BLS-type DLBCL present frequently with haemophagocytic syndrome which often leads to early patient demise. Programmed death ligand 1 (PD-L1) plays a negative regulatory role on effector T cells and is an important target of immunotherapy. Assessment of PD-L1 expression in BLS-type DLBCL may carry therapeutic implications and provide mechanistic insights...
January 14, 2024: Pathology
#25
REVIEW
Ioanna Kantzou, Georgios Sarris, Vasileios Kouloulias, Ioannis Abatzoglou, Vasileios Leivaditis, Konstantinos Grapatsas, Efstratios Koletsis, Athanasios Papatriantafyllou, Manfred Dahm, Admir Mulita, Francesk Mulita, Nikolaos Baltayiannis
Mediastinal tumors encompass a diverse range of malignancies, originating within or spreading to the mediastinum. The administration of radiotherapy within the anatomical confines of the mediastinum presents unique challenges owing to the close proximity of critical organs, including the heart, lungs, esophagus, and spinal cord. However, recent progress in imaging techniques, treatment modalities, and our understanding of tumor biology has significantly contributed to the development of effective and safe therapeutic strategies for mediastinal diseases...
December 2023: Polish Journal of Cardio-Thoracic Surgery
#26
JOURNAL ARTICLE
Major impact of prognosis by age and sex in patients with primary mediastinal large B‑cell lymphoma.
Hsuan-Jen Shih, Ming-Chung Kuo, Tung-Liang Lin, Hsiao-Wen Kao, Jin-Hou Wu, Yu-Shin Hung, Che-Wei Ou, Yi-Jiun Su, Hung Chang
The effective prognostic factors for primary mediastinal large B-cell lymphoma (PMLBCL) vary among published studies. The aim of the present study was to explore the factors influencing the overall survival (OS) and progression-free survival (PFS) of patients with PMLBCL at a single institute in Taiwan. This retrospective study was conducted to analyze the prognostic impact of age, sex, disease stage, International Prognostic Index (IPI) score, treatment modality and initial response. A total of 72 patients with a median age of 28 years were included in the study...
February 2024: Oncology Letters
#27
Kentaro Akata, Kei Yamasaki, Yosuke Chiba, Takako Kawaguchi, Hiroki Dosaka, Toshiki Morimoto, Yasuyuki Higashi, Chinatsu Nishida, Shohei Shimajiri, Kazuhiro Yatera
A 20-year-old Japanese man visited our hospital because an enlarged mediastinal shadow had been detected on chest x-ray. Chest computed tomography revealed a large mediastinal mass with multiple lymph node enlargement, pericardial effusion, and bilateral pleural effusion. He was diagnosed with inflammatory myofibroblastic tumor (IMT) based on a thoracoscopic tumor biopsy. Initial corticosteroid and celecoxib treatment was only partially effective; therefore, additional tumor rebiopsy and left axillary lymph node biopsy were performed...
December 30, 2023: Thoracic Cancer
#28
JOURNAL ARTICLE
Priyanka Mishra, Manoj Prashar, Nidhin Rehman, Anamika Sinha, Deep K Raman
BACKGROUND: Primary extranodal lymphomas (pENL) are lymphomas with minimal nodal involvement and dominant extranodal disease. We aimed to study the prevalence and clinicopathological characteristics of pENL presenting at our center over 5 years from January 2015 to January 2020. METHODS: This is a cross-sectional study of pENL patients in which relevant clinical and laboratory data was collected including demography, site, stage, international prognostic index-revised, imaging findings, hematological, and biochemical parameters and comorbidities including underlying immunodeficiency...
April 17, 2023: Indian Journal of Cancer
#29
JOURNAL ARTICLE
Oren Pasvolsky, Roland L Bassett, Sassine Ghanem, Branko Cuglievan, Priti Tewari, Chitra Hosing, Samer Srour, Jeremy Ramdial, Kris M Mahadeo, Sajad Khazal, Demetrios Petropoulos, Uday Popat, Muzaffar Qazilbash, Partow Kebriaei, Richard Champlin, Elizabeth J Shpall, Yago Nieto
BACKGROUND: There is paucity of data regarding outcomes of children, adolescents and young adults (CAYA) patients with non-Hodgkin lymphoma (NHL) undergoing autologous stem cell transplantation (ASCT). METHODS: Patients aged 0-39 years undergoing first ASCT for NHL at MD Anderson Cancer Center between 2000 and 2020 were analyzed. RESULTS: Two hundred twenty-one patients were included in the analysis, 129 (58%) were male and the median age was 32 (range 6-39) years...
December 20, 2023: BMC Cancer
#30
JOURNAL ARTICLE
Daniel Noerenberg, Franziska Briest, Cornelius Hennch, Kenichi Yoshida, Raphael Hablesreiter, Yasuhide Takeuchi, Hiroo Ueno, Annette M Staiger, Marita Ziepert, Fazila Asmar, Benjamin N Locher, Erika Toth, Thomas Weber, Rose-Marie Amini, Wolfram Klapper, Maria Bouzani, Viola Poeschel, Andreas Rosenwald, Gerhard Held, Elías Campo, Naveed Ishaque, Kostas Stamatopoulos, George Kanellis, Ioannis Anagnostopoulos, Lars Bullinger, Neta Goldschmidt, Pier Luigi Zinzani, Csaba Bödör, Richard Rosenquist, Theodoros P Vassilakopoulos, German Ott, Seishi Ogawa, Frederik Damm
PURPOSE: Primary mediastinal large B-cell lymphoma (PMBCL) is a rare aggressive lymphoma predominantly affecting young female patients. Large-scale genomic investigations and genetic markers for risk stratification are lacking. PATIENTS AND METHODS: To elucidate the full spectrum of genomic alterations, samples from 340 patients with previously untreated PMBCL were investigated by whole-genome (n = 20), whole-exome (n = 78), and targeted (n = 308) sequencing. Statistically significant prognostic variables were identified using a multivariable Cox regression model and confirmed by L1/L2 regularized regressions...
February 1, 2024: Journal of Clinical Oncology
#31
JOURNAL ARTICLE
Theodoros P Vassilakopoulos, Alexia Piperidou, Zois Mellios, Evgenia Verigou, Eirini Katodritou, Christina Kalpadakis, Sotirios G Papageorgiou, Chrysovalantou Chatzidimitriou, Vassilios Prassopoulos, Marina P Siakantaris, Hara Giatra, Dimitrios Karantanis, Nikolaos Papathanasiou, Loukia Ligdi, Anastasia Kopsaftopoulou, Theoni Leonidopoulou, Vasileios Xanthopoulos, Stamatios Karakatsanis, Effimia Vrakidou, Sophia Chatziioannou, Dimitrios Drougkas, Eleftheria Hatzimichael, Gabriella Gainaru, Maria Palassopoulou, Maria Tsirogianni, Maria Kotsopoulou, Gerassimos Tsourouflis, Evangelia Skoura, Catherine Mainta, Evangelos Terpos, Christos Poziopoulos, Theodora Triantafyllou, Panayiotis Zikos, Argyro Koumarianou, Dimitra Liapi, Vassiliki Pappa, Evgenia Verrou, Panayiotis Tsirigotis, Vassiliki Labropoulou, Helen Papadaki, Ioannis Datseris, Argiris Symeonidis, Maria Bouzani, Maria Bakiri, Themis Karmiris, Maria K Angelopoulou, Phivi Rondogianni
No abstract text is available yet for this article.
November 2023: HemaSphere
#32
JOURNAL ARTICLE
Nader Kim El-Mallawany, Lisa Giulino-Roth, John M Burke, Michelle Hermiston, Carl E Allen
Pediatric non-Hodgkin lymphoma includes over 30 histologies (many with subtypes), with approximately 800 cases per year in the US, compared to >60,000 cases of adult NHL annually. Improvements in survival in pediatric and adolescent mature B cell NHL over the past 5 decades align with the overall success of the cooperative trial model with dramatic improvements in outcomes through dose escalation of chemotherapy and, more recently, targeted therapy with rituximab. Pediatric dose-intense strategies carry risks of long-term consequences, but treatment failure is nearly universally fatal...
November 2023: EJHaem
#33
REVIEW
Christian Steidl, Robert Kridel, Michael Binkley, Lindsay M Morton, Amy Chadburn
Lymphoid cancers are among the most frequent cancers diagnosed in adolescents and young adults (AYA), ranging from approximately 30%-35% of cancer diagnoses in adolescent patients (age 10-19) to approximately 10% in patients aged 30-39 years. Moreover, the specific distribution of lymphoid cancer types varies by age with substantial shifts in the subtype distributions between pediatric, AYA, adult, and older adult patients. Currently, biology studies specific to AYA lymphomas are rare and therefore insight into age-related pathogenesis is incomplete...
November 2023: EJHaem
#34
JOURNAL ARTICLE
Janet Bouttell, Heather Fraser, John R Goodlad, David Hopkins, Pam McKay, Karin A Oien, Bruce Seligmann, Stephan von Delft, Neil Hawkins
BACKGROUND AND OBJECTIVE: Adding gene expression profiles (GEPs) to the current diagnostic work-up of aggressive large B-cell lymphomas may lead to the reclassification of patients, treatment changes and improved outcomes. A GEP test is in development using TempO-Seq® technology to distinguish Burkitt lymphoma (BL) and primary mediastinal large B-cell lymphoma (PMBCL) from diffuse large B-cell lymphoma (DLBCL), and to classify patients with DLBLC and to predict the benefit of (e...
November 28, 2023: Applied Health Economics and Health Policy
#35
JOURNAL ARTICLE
Sarah Almuqbil, Amal AlHarbi, Fatimah S Alzouri, Hatem Yazeed Elbawab, Noor S Alsafwani, Zahra Alkhunaizy
BACKGROUND Myasthenia gravis is a neuromuscular disorder that is strongly associated with thymoma. Although the presence of myasthenia gravis with other tumors is uncommon, approximately 50% of patients with thymoma have myasthenia gravis. Thymic Hodgkin lymphoma should be considered due to the multiple reported cases of patients with myasthenia gravis and Hodgkin lymphoma. In this report, we present the case of 24-year-old woman with myasthenia gravis who was incidentally found to have coexisting thymoma with thymic Hodgkin lymphoma...
November 25, 2023: American Journal of Case Reports
#36
REVIEW
Hiroo Katsuya, Junji Suzumiya, Shinya Kimura
Immunotherapy with the programmed cell death protein 1 (PD-1)/PD-1 ligand (PD-L1) blockade has revolutionized the treatment of advanced solid cancers. However, these clinical benefits have been limited to cases of malignant lymphomas, showing promising results for only classic Hodgkin lymphoma (cHL) and primary mediastinal B-cell lymphoma (PMBCL). To bring clinical benefits to more patients with lymphoma, numerous combination therapies involving PD-1/PD-L1 blockade have been tested in clinical trials in both frontline and relapsed/refractory settings...
November 14, 2023: Cancers
#37
JOURNAL ARTICLE
Alison Hayes, Katherine Hughes, Cassia Hare, Lorraine Peschard, Armando S Lara, Luca Schiavo, Jane Dobson
A mediastinal mass was diagnosed in a 7-year-4-month-old neutered female mixed breed dog following a 3-week history of lethargy, hyporexia and pyrexia. Bi-cavitary imaging, needle aspirate cytology and flow cytometry confirmed WHO clinical stage IVb, intermediate to large T-cell lymphoma involving the mediastinum, liver and spleen. The dog initially responded to a multidrug chemotherapy protocol but clinical deterioration occurred 3 months later. The dog presented with anorexia, vomiting and diarrhoea, associated with marked faecal tenesmus and haematochezia, initially believed by the primary care practitioner to be related to chemotherapy toxicity...
November 2023: Journal of Comparative Pathology
#38
REVIEW
Alexander Fichtner, Alexander Marx, Philipp Ströbel, Felix Bremmer
This article will review current aspects of the histopathological, immunohistochemical and molecular analysis of primary mediastinal germ cell tumours (PMGCTs) as well as their aetiological, epidemiological, clinical and therapeutic features. PMGCTs represent an important differential diagnosis in the spectrum of mediastinal tumours, and their diagnosis is usually made on small tissue samples from core needle biopsies in combination with diagnostic imaging and serum tumour markers. As in lymphomas, a small biopsy is often the only viable tumour sample available from these patients, as they receive chemotherapy prior to eventual surgical resection...
January 2024: Histopathology
#39
JOURNAL ARTICLE
Sanshiro Nakao, Sho Tanaka, Kazuki Abe, Tomomi Komiyama, Yoshiya Sugiura, Chiaki Nakaseko, Naomi Shimizu
In recent years, lesbian, gay, bisexual, and transgender (LGBT) populations have been gaining acceptance in society. However, very few cases of malignancy in the LGBT population have been reported thus far. We herein report a transgender woman receiving estrogen supplementation who developed primary mediastinal large B-cell lymphoma (PMBCL) and was treated with dose-adjusted EPOCH-rituximab (DA-EPOCH-R) therapy. The patient achieved complete remission after the sixth course of DA-EPOCH-R therapy. To help this LGBT patient continue receiving chemotherapy smoothly on admission, adjusting the hospital environment, such as the allocation of rooms, was essential...
November 20, 2023: Internal Medicine
#40
JOURNAL ARTICLE
Roxana Maria Tudor, Elsheikh Mohammed Ali, Salman Ullah Khan, John McDermott
Klinefelter syndrome (KS) is the most common cause of primary hypogonadism in male patients; however, the diagnosis of KS is frequently delayed or missed. This delay can lead to undesirable outcomes for patients, especially considering that individuals with KS have a higher risk of developing specific malignancies, including breast cancer, non-Hodgkin's lymphoma and mediastinal germ cell tumours. We present a case of a male patient in his 60s, where the established diagnosis of metastatic bilateral breast cancer prompted us to investigate and subsequently confirm a diagnosis of KS...
November 15, 2023: BMJ Case Reports
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
